Launching an offensive against the Prime Minister over price rise, Rahul Gandhi today said after coming to power Narendra Modi has ignored the issue and demanded that he should give a date by when the prices of pulses will drop.&nbsp; 
 
&quot;You may make as many hollow promises as you want, but give us a date by when the prices of daal will come down,&quot; Gandhi said in Lok Sabha during a debate on price rise. 
 
In his first major intervention in the monsoon session, Gandhi said the price of pulses and vegetables have gone over the roof after NDA came to power, and farmers have not been able to get any benefit of the steep rise in the price of these commodities. 
 
Recalling Modi&#39;s speech at a poll rally in Himachal Pradesh in February 2014, Gandhi said while attacking the then UPA government over the issue, he had said that &quot;Ma-bachche raat raat rote hain, aasoon pee ke sote hain&quot; (mother and child cry the whole night and sleep drinking their tears). 
 
&quot;What a dialogue,&quot; Gandhi said thrice, taking a dig at Modi who was not present in the House. 
 
&quot;I want to remind the Prime Minister of the promises he made to people of the country during the poll campaign, which Modiji does not talk about now and has forgotten. He had also promised that when the BJP government comes to power, it will bring down the prices,&quot; Gandhi said. 
 
Listing out the prices of vegetables and pulses, Gandhi said in 2014, the price of tomato was Rs 18, which has shot up to Rs 55 in 2016. Urad and tur dal, priced at Rs 70 and 75 in February 2014, has gone up to Rs 160 and Rs 180 this month. 
 
He said there was a gap between the minimum support price for tur dal given to the farmers. It was Rs 45 whereas its price in the market was Rs 75. Now, the MSP has risen to Rs 50, but the price of the pulses is now Rs 180.&nbsp; 
 
&quot;So, there is a gap of Rs 130 in the NDA government. Where is this Rs 100 going?&quot; Gandhi asked. &quot;During elections, Modiji had said, &#39;Make me a chowkidar&#39; (watchman).&nbsp;Now, there is a theft of dal under the very nose of the chowkidar. But the chowkidar has not uttered a word. He is mum. Now he has become a big person. Leave that job of chowkidari to the Congress,&quot; Gandhi said.&nbsp; 
 
In reference to a BJP slogan &#39;Har Har Modi&#39; used during the Lok Sabha polls, he said, &quot;Now people are saying &#39;Arhar Modi&#39;.&quot; Taking a jibe at NDA&#39;s second birthday celebrations, the Congress vice president said the Prime Minister did not even utter a single word about rising prices during this event, and sought to know why. 
 
Accusing the government of waiving off Rs 52,000 crore of the corporates, Gandhi asked what benefit the government has given to the farmers and housewives of the savings amounting to Rs 2 lakh crore it has made from the slump in the crude prices. He also questioned NDA&#39;s flagship programmes like Make in India, Stand Up India and said, &quot;The &#39;Make in India&#39; programme has not got given a single job to the youth&quot;. 
 
(PTI)

The Congress vice president said the PM did not even utter a single word about rising prices. 'Now people are saying 'Arhar Modi''

Launching an offensive against the Prime Minister over price rise, Rahul Gandhi today said after coming to power Narendra Modi has ignored the issue and demanded that he should give a date by when the prices of pulses will drop. "You may make as many hollow promises as you want, but give us a date by when the prices of daal will come down," Gandhi said in Lok Sabha during a debate on price rise. In his first major intervention in the monsoon session, Gandhi said the price of pulses and vegetables have gone over the roof after NDA came to power, and farmers have not been able to get any benefit of the steep rise in the price of these commodities. Recalling Modi's speech at a poll rally in Himachal Pradesh in February 2014, Gandhi said while attacking the then UPA government over the issue, he had said that "Ma-bachche raat raat rote hain, aasoon pee ke sote hain" (mother and child cry the whole night and sleep drinking their tears). "What a dialogue," Gandhi said thrice, taking a dig at Modi who was not present in the House. "I want to remind the Prime Minister of the promises he made to people of the country during the poll campaign, which Modiji does not talk about now and has forgotten. He had also promised that when the BJP government comes to power, it will bring down the prices," Gandhi said. Listing out the prices of vegetables and pulses, Gandhi said in 2014, the price of tomato was Rs 18, which has shot up to Rs 55 in 2016. Urad and tur dal, priced at Rs 70 and 75 in February 2014, has gone up to Rs 160 and Rs 180 this month. He said there was a gap between the minimum support price for tur dal given to the farmers. It was Rs 45 whereas its price in the market was Rs 75. Now, the MSP has risen to Rs 50, but the price of the pulses is now Rs 180. "So, there is a gap of Rs 130 in the NDA government. Where is this Rs 100 going?" Gandhi asked. "During elections, Modiji had said, 'Make me a chowkidar' (watchman). Now, there is a theft of dal under the very nose of the chowkidar. But the chowkidar has not uttered a word. He is mum. Now he has become a big person. Leave that job of chowkidari to the Congress," Gandhi said. In reference to a BJP slogan 'Har Har Modi' used during the Lok Sabha polls, he said, "Now people are saying 'Arhar Modi'." Taking a jibe at NDA's second birthday celebrations, the Congress vice president said the Prime Minister did not even utter a single word about rising prices during this event, and sought to know why. Accusing the government of waiving off Rs 52,000 crore of the corporates, Gandhi asked what benefit the government has given to the farmers and housewives of the savings amounting to Rs 2 lakh crore it has made from the slump in the crude prices. He also questioned NDA's flagship programmes like Make in India, Stand Up India and said, "The 'Make in India' programme has not got given a single job to the youth". (PTI)

Give a date by when pulses price will decline: Gandhi scion tells Indian Prime Minister Modi

Even though Apple&rsquo;s new iPhones will be unveiled in two months, rumours regarding their price have already surfaced online. According to a new leak the company will offer three iPhone variants namely iPhone 7, iPhone 7 Plus and iPhone 7 Pro. 
 
A report by Weibo shares the rumoured prices of the devices. 
 
iPhone 7 
 
32GB variant - CNY 5,288 (approximately Rs 52,900) 
 
64GB variant at CNY 6,088 (approximately Rs 60,900) 
 
256GB at CNY 7,088 (approximately Rs 70,900) 
 
iPhone 7 Plus 
 
32GB variant - CNY 6,088 (approximately Rs 60,900) 
 
128GB variant - CNY 6,888 (approximately Rs 68,900) 
 
256GB variant - CNY 7,888 (approximately Rs 78,900) 
 
iPhone 7 Pro 
 
32GB variant - CNY 7,088 (approximately Rs 70,900) 
 
128GB variant &ndash; CNY 7,888 (approximately Rs 78,900) 
 
256GB variant - 8,882 (approximately Rs 88,900) 
 
Additionally, the iPhone 7 is likely to drop the headphone jack, and will instead offer earpods with Lightning Connector. According to images shared on Weibo, the new EarPods look similar to the company existing earbuds. However, Apple has ditched the 3.5mm connector and now offers a reversible Lightning port for digital sound. 
 
(DNA) 
 
 
 
&nbsp;

Additionally, the iPhone 7 is likely to drop the headphone jack, and will instead offer earpods with Lightning Connector

Even though Apple’s new iPhones will be unveiled in two months, rumours regarding their price have already surfaced online. According to a new leak the company will offer three iPhone variants namely iPhone 7, iPhone 7 Plus and iPhone 7 Pro. A report by Weibo shares the rumoured prices of the devices. iPhone 7 32GB variant - CNY 5,288 (approximately Rs 52,900) 64GB variant at CNY 6,088 (approximately Rs 60,900) 256GB at CNY 7,088 (approximately Rs 70,900) iPhone 7 Plus 32GB variant - CNY 6,088 (approximately Rs 60,900) 128GB variant - CNY 6,888 (approximately Rs 68,900) 256GB variant - CNY 7,888 (approximately Rs 78,900) iPhone 7 Pro 32GB variant - CNY 7,088 (approximately Rs 70,900) 128GB variant – CNY 7,888 (approximately Rs 78,900) 256GB variant - 8,882 (approximately Rs 88,900) Additionally, the iPhone 7 is likely to drop the headphone jack, and will instead offer earpods with Lightning Connector. According to images shared on Weibo, the new EarPods look similar to the company existing earbuds. However, Apple has ditched the 3.5mm connector and now offers a reversible Lightning port for digital sound. (DNA)

Leaked: Apple iPhone 7, iPhone 7 Plus and iPhone 7 Pro pricing spotted online

Asian stocks were on a weak footing on Wednesday as a slip in crude oil prices dampened investors&#39; appetite for riskier assets, while the recently bullish dollar stalled against the Euro and Yen following a mixed bag of U.S. economic data.

Spreadbetters also expected a shaky start for European shares, forecasting Britain&#39;s FTSE, Germany&#39;s DAX and France&#39;s CAC to open flat to slightly lower.

Japan&#39;s Nikkei lost more than one percent as the yen firmed. Other decliners included Australian stocks&nbsp;which fell 1.0 percent.

Hong Kong&#39;s Hang Seng and South Korea&#39;s KOSPI stood little changed.

Shanghai see-sawed in and out of negative terrain, and was last up 0.1 percent, after rallying on Tuesday on expectations MSCI could add China&#39;s mainland stocks to its emerging market benchmark for the first time.

David Dai, Shanghai-based investor director at Nanhai Fund Management Co, said any market rally was unlikely to be sustainable at this stage.

&quot;The economy is still weak, and the Fed will likely raise rates soon. I don&#39;t think the market will go up much further. The best strategy now is to take profit.&quot;

There was little market reaction to the official and private surveys on China&#39;s manufacturing activity, which were roughly in line with expectations, suggesting the world&#39;s second-largest economy is still struggling to regain traction.

The Caixin/Markit Manufacturing Purchasing Managers&#39; index (PMI) showed activity at China&#39;s factories shrank for a 15th straight month in May. The official manufacturing May PMI painted a slightly more optimistic picture and stood unchanged from the previous month at 50.1

MSCI&#39;s broadest index of Asia-Pacific shares outside Japan recovered from an earlier dip and crawled up 0.1 percent.

The Dow shed 0.5 percent and the S&amp;P 500 dipped 0.1 percent on Tuesday, as energy shares weakened in the wake of a slip in oil prices and offset a rise in safe-haven utilities.

Crude pulled back from eight-month highs reached last week amid expectations that a global glut was easing, falling overnight to profit taking. U.S. crude was last down 0.7 percent at $48.76 a barrel and Brent fell 0.8 percent to $49.51.

The fall in oil prices was exacerbated after United Arab Emirates Oil Minister Suhail bin Mohammed al-Mazroui said he was happy with the oil market, noting that prices had been correcting higher.

The UAE oil minister&#39;s comments touched a nerve in a market wary that an OPEC meeting on Thursday may not pave the way for a production freeze.

&quot;The political will of the OPEC countries to enact a production freeze is clearly waning. A production freeze is unlikely to come up as an agenda at the June meeting,&quot; wrote Yoshimasa Maruyama, chief market economist at SMBC Nikko Securities in Tokyo.

&quot;A sense of crisis among the oil producing countries appears to have receded following the recent spike in crude oil prices.&quot;

In currencies, the dollar was down 0.6 percent at 110.010 yen, having come off a one-month high of 111.455 struck on Monday after Federal Reserve Chair Janet Yellen&#39;s comments raised expectations for a near-term U.S. rate hike.

The Euro was at $1.1120, putting some distance between a 2-1/2-month low of $1.1097 touched on Monday.

U.S. data overnight saw personal income-related and housing indicators come in strong, while the Chicago manufacturing PMI and consumer confidence data proved disappointing.

The Australian Dollar was up 0.6 percent to $0.7277 helped by stronger-than-expected first quarter economic growth, which pushed it further away from last week&#39;s three-month low of $0.7145.

Sterling was on the defensive, last trading little changed at $1.4490 after dropping more than one percent on Tuesday, after polls showing those who support Brexit may be increasing.

investors lose hope as the price of oil slips further

Asian stocks were on a weak footing on Wednesday as a slip in crude oil prices dampened investors' appetite for riskier assets, while the recently bullish dollar stalled against the Euro and Yen following a mixed bag of U.S. economic data. Spreadbetters also expected a shaky start for European shares, forecasting Britain's FTSE, Germany's DAX and France's CAC to open flat to slightly lower. Japan's Nikkei lost more than one percent as the yen firmed. Other decliners included Australian stocks which fell 1.0 percent. Hong Kong's Hang Seng and South Korea's KOSPI stood little changed. Shanghai see-sawed in and out of negative terrain, and was last up 0.1 percent, after rallying on Tuesday on expectations MSCI could add China's mainland stocks to its emerging market benchmark for the first time. David Dai, Shanghai-based investor director at Nanhai Fund Management Co, said any market rally was unlikely to be sustainable at this stage. "The economy is still weak, and the Fed will likely raise rates soon. I don't think the market will go up much further. The best strategy now is to take profit." There was little market reaction to the official and private surveys on China's manufacturing activity, which were roughly in line with expectations, suggesting the world's second-largest economy is still struggling to regain traction. The Caixin/Markit Manufacturing Purchasing Managers' index (PMI) showed activity at China's factories shrank for a 15th straight month in May. The official manufacturing May PMI painted a slightly more optimistic picture and stood unchanged from the previous month at 50.1 MSCI's broadest index of Asia-Pacific shares outside Japan recovered from an earlier dip and crawled up 0.1 percent. The Dow shed 0.5 percent and the S&P 500 dipped 0.1 percent on Tuesday, as energy shares weakened in the wake of a slip in oil prices and offset a rise in safe-haven utilities. Crude pulled back from eight-month highs reached last week amid expectations that a global glut was easing, falling overnight to profit taking. U.S. crude was last down 0.7 percent at $48.76 a barrel and Brent fell 0.8 percent to $49.51. The fall in oil prices was exacerbated after United Arab Emirates Oil Minister Suhail bin Mohammed al-Mazroui said he was happy with the oil market, noting that prices had been correcting higher. The UAE oil minister's comments touched a nerve in a market wary that an OPEC meeting on Thursday may not pave the way for a production freeze. "The political will of the OPEC countries to enact a production freeze is clearly waning. A production freeze is unlikely to come up as an agenda at the June meeting," wrote Yoshimasa Maruyama, chief market economist at SMBC Nikko Securities in Tokyo. "A sense of crisis among the oil producing countries appears to have receded following the recent spike in crude oil prices." In currencies, the dollar was down 0.6 percent at 110.010 yen, having come off a one-month high of 111.455 struck on Monday after Federal Reserve Chair Janet Yellen's comments raised expectations for a near-term U.S. rate hike. The Euro was at $1.1120, putting some distance between a 2-1/2-month low of $1.1097 touched on Monday. U.S. data overnight saw personal income-related and housing indicators come in strong, while the Chicago manufacturing PMI and consumer confidence data proved disappointing. The Australian Dollar was up 0.6 percent to $0.7277 helped by stronger-than-expected first quarter economic growth, which pushed it further away from last week's three-month low of $0.7145. Sterling was on the defensive, last trading little changed at $1.4490 after dropping more than one percent on Tuesday, after polls showing those who support Brexit may be increasing.

Asia wavers as oil slip sinks sentiment, dollar stalls

New hepatitis C drugs that can cure the liver-destroying disease are revolutionising treatment, but their high price is a huge burden in some countries, particularly in Central and Eastern Europe, according to a new study.

An analysis of prices for two Gilead&nbsp;drugs by World&nbsp;Health&nbsp;Organization (WHO) experts, published on Tuesday, found that while US&nbsp;prices were higher in dollar terms, parts of Europe paid considerably more in &quot;purchasing-power parity&quot; terms.

Purchasing-power parity, or PPP, is used to normalise price comparisons between different economies by taking into account the price of similar baskets of goods instead of market foreign exchange rates.

The PPP-adjusted price in Poland of a treatment course with Gilead&#39;s Harvoni was $118,754, against $72,765 in the U.S., the study found, and it would cost 190.5 percent of the country&#39;s total drugs budget to treat all Polish patients.

Another Gilead drug, Sovaldi, had a similar nominal price in both Norway and Slovakia, but on a PPP basis the price was more than twice as much in Slovakia.

&quot;If you want to treat all patients with hepatitis C, then the prices countries are being asked to pay - even after price negotiations - are still way too high,&quot; said study author Suzanne Hill, the WHO&#39;s director of essential medicines.

The study, which took account of probable confidential discounts on prices, was published in the journal PLOS Medicine.

The cost of Gilead&#39;s hepatitis C drugs has been contentious since the U.S. approval of Sovaldi in 2013, although the company has taken several steps to offer discounts and provide access programmes.

This includes allowing Indian drug companies to manufacture much lower-cost versions of the medicines for sale in developing countries.

Gilead says the price of its treatments reflect their clinical, economic and public&nbsp;health&nbsp;value, arguing that they are cost-effective over the long term.

Hill and colleagues don&#39;t question the value of the drugs but argue that without lower prices, countries will not be able to roll them out on a sufficient scale to minimise the burden of hepatitis C.

&quot;Current prices of these medicines are variable and unaffordable globally,&quot; they concluded.

New hepatitis C drugs that can cure the liver-destroying disease are revolutionising treatment, but their high price is a huge burden in Central and Eastern Europe

New hepatitis C drugs that can cure the liver-destroying disease are revolutionising treatment, but their high price is a huge burden in some countries, particularly in Central and Eastern Europe, according to a new study. An analysis of prices for two Gilead drugs by World Health Organization (WHO) experts, published on Tuesday, found that while US prices were higher in dollar terms, parts of Europe paid considerably more in "purchasing-power parity" terms. Purchasing-power parity, or PPP, is used to normalise price comparisons between different economies by taking into account the price of similar baskets of goods instead of market foreign exchange rates. The PPP-adjusted price in Poland of a treatment course with Gilead's Harvoni was $118,754, against $72,765 in the U.S., the study found, and it would cost 190.5 percent of the country's total drugs budget to treat all Polish patients. Another Gilead drug, Sovaldi, had a similar nominal price in both Norway and Slovakia, but on a PPP basis the price was more than twice as much in Slovakia. "If you want to treat all patients with hepatitis C, then the prices countries are being asked to pay - even after price negotiations - are still way too high," said study author Suzanne Hill, the WHO's director of essential medicines. The study, which took account of probable confidential discounts on prices, was published in the journal PLOS Medicine. The cost of Gilead's hepatitis C drugs has been contentious since the U.S. approval of Sovaldi in 2013, although the company has taken several steps to offer discounts and provide access programmes. This includes allowing Indian drug companies to manufacture much lower-cost versions of the medicines for sale in developing countries. Gilead says the price of its treatments reflect their clinical, economic and public health value, arguing that they are cost-effective over the long term. Hill and colleagues don't question the value of the drugs but argue that without lower prices, countries will not be able to roll them out on a sufficient scale to minimise the burden of hepatitis C. "Current prices of these medicines are variable and unaffordable globally," they concluded.

Burden of pricey hepatitis C drugs heaviest in Eastern Europe

price

Price, News on Price, stories on Price, articles on Price, Price stories at Wion, Price news, Price latest news